• Mar
    06
    2015

    Name: Prof. Mark W. GRINSTAFF

    Affiliation: Boston University

    Location: Chemistry Seminar Room

    Hour: 14:00

    The most effective treatment for stage I patients with localized non-small cell lung cancer (NSCLC) is surgical resection. However, if disease recurs, the long-term survival is dismal with a 2-year survival of only ≈20%.  The risk of local recurrence in early stage lung cancer is greater in patients receiving smaller sublobar resection compared to larger lobectomy. At the surgical resection margin, residual microscopic tumor cells remain and are present in ≈40% of patients following a “curative” wedge resection, demonstrating a need to treat those remaining cancer cells. We have designed, synthesized, and evaluated three types of polymeric drug delivery devices (nanoparticles, hydrophobic films, and superhydrophobic meshes), which can be implanted at the time of resection surgery. Specifically, I will discuss the: 1) synthesis of these materials; 2) material properties; 3) in vitro cytotoxicity; and 4) in vivo performance as well as the advantages and limitations of each of these approaches using nanoparticles, hydrophobic films, or superhydrophobic meshes towards preventing tumor recurrence following surgery.